Analysis of Antibiotic Exposure and Early-Onset Neonatal Sepsis in Europe, North America, and Australia
Authors: Eric Giannoni, Varvara Dimopoulou, Claus Klingenberg, Lars Navér, Viveka Nordberg, Alberto Berardi, Salhab el Helou, Gerhard Fusch, Joseph M. Bliss, Dirk Lehnick, Nicholas Guerina, Joanna Seliga-Siwecka, Pierre Maton, Donatienne Lagae, Judit Mari, Jan Janota, Philipp K. A. Agyeman, Riccardo Pfister, Giuseppe Latorre, Gianfranco Maffei, Nicola Laforgia, Enikő Mózes, Ketil Størdal, Tobias Strunk, Martin Stocker, Maria Grazia Capretti, Martina Ceccoli, Morena De Angelis, Pietro Drimaco, Khalyane Eap, Zoe el Helou, Rana Esmaeilizand, Alessandra Foglianese, Carmelo Geraci, Bartłomiej Grochowski, Stellan Håkansson, Sharandeep Kaur, Anne-Louise Kollegger, Frida Oldendorff, Vittoria Rizzo, Arild E. Rønnestad, Damber Shrestha, Hans Jørgen Stensvold, Anaïs Torregrossa, Martin Trefny, Kristyna Zilinska, Aleksandra Zwijacz
Journal: JAMA Network Open (2022)

Appropriate use of antibiotics is life-saving in neonatal early-onset sepsis (EOS), but overuse of antibiotics is associated with antimicrobial resistance and long-term adverse outcomes. Large international studies quantifying early-life antibiotic exposure along with EOS incidence are needed to provide a basis for future interventions aimed at safely reducing neonatal antibiotic exposure.To compare early postnatal exposure to antibiotics, incidence of EOS, and mortality among different networks in high-income countries.This is a retrospective, cross-sectional study of late-preterm and full-term neonates born between January 1, 2014, and December 31, 2018, in 13 hospital-based or population-based networks from 11 countries in Europe and North America and Australia. The study included all infants born alive at a gestational age greater than or equal to 34 weeks in the participating networks. Data were analyzed from October 2021 to March 2022.Exposure to antibiotics started in the first postnatal week.The main outcomes were the proportion of late-preterm and full-term neonates receiving intravenous antibiotics, the duration of antibiotic treatment, the incidence of culture-proven EOS, and all-cause and EOS-associated mortality.A total of 757 979 late-preterm and full-term neonates were born in the participating networks during the study period; 21 703 neonates (2.86%; 95% CI, 2.83%-2.90%), including 12 886 boys (59.4%) with a median (IQR) gestational age of 39 (36-40) weeks and median (IQR) birth weight of 3250 (2750-3750) g, received intravenous antibiotics during the first postnatal week. The proportion of neonates started on antibiotics ranged from 1.18% to 12.45% among networks. The median (IQR) duration of treatment was 9 (7-14) days for neonates with EOS and 4 (3-6) days for those without EOS. This led to an antibiotic exposure of 135 days per 1000 live births (range across networks, 54-491 days per 1000 live births). The incidence of EOS was 0.49 cases per 1000 live births (range, 0.18-1.45 cases per 1000 live births). EOS-associated mortality was 3.20% (12 of 375 neonates; range, 0.00%-12.00%). For each case of EOS, 58 neonates were started on antibiotics and 273 antibiotic days were administered.The findings of this study suggest that antibiotic exposure during the first postnatal week is disproportionate compared with the burden of EOS and that there are wide (up to 9-fold) variations internationally. This study defined a set of indicators reporting on both dimensions to facilitate benchmarking and future interventions aimed at safely reducing antibiotic exposure in early life.